Healthcare Sales & Marketing Network News: Autogel

Searching News Database: Autogel

HSMN NewsFeed - 1 Jul 2014
Ipsen submits marketing authorization applications in the US and Europe for Somatuline(R) (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Jun 2008
Tercica Announces Results from Increlex(R) IGFD Patient Registry and Other Increlex(R) Studies at the 90th Meeting of the Endocrine Society
Biopharmaceuticals

HSMN NewsFeed - 31 Aug 2007
Ipsen: Somatuline(R) Depot Receives Marketing Approval in the United States for the Treatment of Acromegaly
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 30 Aug 2007
Somatuline(R) Depot Receives FDA Marketing Approval for the Treatment of Acromegaly
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Jan 2007
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Accepted for Filing by FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Jan 2007
FDA Accepts for Filing a New Drug Application (NDA) for Somatuline(R) Autogel(R)
Biopharmaceuticals

HSMN NewsFeed - 2 Nov 2006
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Submitted to FDA
Biopharmaceuticals

HSMN NewsFeed - 16 Oct 2006
Ipsen and Tercica Complete Worldwide Strategic Collaboration Agreement in Endocrinology
Biopharmaceuticals Endocrinology Licensing

Return to NewsFeed

Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 1 additional stories matching:
Autogel
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.